{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:44:05Z","timestamp":1793454245823,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n There is a need for observational studies to supplement evidence from clinical trials, and the target trial emulation (TTE) framework can help avoid biases that can be introduced when treatments are compared crudely using observational data by applying design principles for randomized clinical trials. Adalimumab (ADA) and tofacitinib (TOF) were shown to be equivalent in patients with rheumatoid arthritis (RA) in a randomized clinical trial, but to our knowledge, these drugs have not been compared head-to-head using routinely collected clinical data and the TTE framework.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To emulate a randomized clinical trial comparing ADA vs TOF in patients with RA who were new users of a biologic or targeted synthetic disease-modifying antirheumatic drug (b\/tsDMARD).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This comparative effectiveness study emulating a randomized clinical trial of ADA vs TOF included Australian adults aged 18 years or older with RA in the Optimising Patient Outcomes in Australian Rheumatology (OPAL) data set. Patients were included if they initiated ADA or TOF between October 1, 2015, and April 1, 2021; were new b\/tsDMARD users; and had at least 1 component of the disease activity score in 28 joints using C-reactive protein (DAS28-CRP) recorded at baseline or during follow-up.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Treatment with either ADA (40 mg every 14 days) or TOF (10 mg daily).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was the estimated average treatment effect, defined as the difference in mean DAS28-CRP among patients receiving TOF compared with those receiving ADA at 3 and 9 months after initiating treatment. Missing DAS28-CRP data were multiply imputed. Stable balancing weights were used to account for nonrandomized treatment assignment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 842 patients were identified, including 569 treated with ADA (387 [68.0%] female; median age, 56 years [IQR, 47-66 years]) and 273 treated with TOF (201 [73.6%] female; median age, 59 years [IQR, 51-68 years]). After applying stable balancing weights, mean DAS28-CRP in the ADA group was 5.3 (95% CI, 5.2-5.4) at baseline, 2.6 (95% CI, 2.5-2.7) at 3 months, and 2.3 (95% CI, 2.2-2.4) at 9 months; in the TOF group, it was 5.3 (95% CI, 5.2-5.4) at baseline, 2.4 (95% CI, 2.2-2.5) at 3 months, and 2.3 (95% CI, 2.1-2.4) at 9 months. The estimated average treatment effect was \u22120.2 (95% CI, \u22120.4 to \u22120.03;\n P<\/jats:italic>\n \u2009=\u2009.02) at 3 months and \u22120.03 (95% CI, \u22120.2 to 0.1;\n P<\/jats:italic>\n \u2009=\u2009.60) at 9 months.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, there was a modest but statistically significant reduction in DAS28-CRP at 3 months for patients receiving TOF compared with those receiving ADA and no difference between treatment groups at 9 months. Three months of treatment with either drug led to clinically relevant average reductions in mean DAS28-CRP, consistent with remission.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.20851","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T11:32:57Z","timestamp":1688038377000},"page":"e2320851","source":"Crossref","is-referenced-by-count":16,"title":["Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia"],"prefix":"10.1001","volume":"6","author":[{"given":"Claire T.","family":"Deakin","sequence":"first","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"},{"name":"Centre for Adolescent Rheumatology Versus Arthritis at University College London, University College London Hospitals, Great Ormond Street Hospital and University College London, London, United Kingdom"},{"name":"National Institute of Health Research Biomedical Centre at Great Ormond Street Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca L.","family":"De Stavola","sequence":"additional","affiliation":[{"name":"Population, Policy and Practice Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Littlejohn","sequence":"additional","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"},{"name":"Department of Medicine, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedley","family":"Griffiths","sequence":"additional","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"},{"name":"Barwon Rheumatology Service, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Ciciriello","sequence":"additional","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"},{"name":"Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Youssef","sequence":"additional","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"},{"name":"Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"},{"name":"University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mathers","sequence":"additional","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"},{"name":"Georgetown Arthritis, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bird","sequence":"additional","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"},{"name":"University of New South Wales, Kensington, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tegan","family":"Smith","sequence":"additional","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"OPAL Rheumatology Ltd, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Freeman","sequence":"additional","affiliation":[{"name":"Software for Specialists Pty Ltd, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Segelov","sequence":"additional","affiliation":[{"name":"Software for Specialists Pty Ltd, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Software for Specialists Pty Ltd, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun R.","family":"Seaman","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"OPAL Rheumatology Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rischin","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Scott-Charlton","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alannah","family":"Quinlivan","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Stockman","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Capon","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ananda","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Foote","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dorai-Raj","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Finniss","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Sweeney","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armi","family":"Salonga","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvin","family":"Damodaran","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Hennessey","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bain","family":"Shenstone","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Kane","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Sutu","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Omidvar","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Champa","family":"Nataraja","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Inderjeeth","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiwai","family":"Tong","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Mack","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Barrett","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sumpton","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Boulos","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lewis","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Nicholls","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mathers","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deb","family":"Speden","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Chessman","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickson","family":"MA","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ong","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evange","family":"Romas","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Laska","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Joshua","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Strickland","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene-Siew","family":"Ngian","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Littlejohn","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Tracey","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedley","family":"Griffiths","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Cooley","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Telegdy","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hutton","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky","family":"Chay","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Oliver","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Zochling","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ly","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Moxey","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Harmer","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Wang","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianna","family":"He","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Hall","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"May","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Moi","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"vander-Kallen","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Aw","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Pui","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Franklyn","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Gregory-Wong","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Tymms","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Morrisroe","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Over","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Cai","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Khoo","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Maguire","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiri","family":"Langford","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kokum","family":"Dissanayake","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Yap","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Girgis","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Young","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Alblas","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les","family":"Barnsley","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Deveza","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Voight","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Croyle","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Handel","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Turner","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maninder","family":"Mundae","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree","family":"Micallef","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Feletar","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Arnold","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Collins","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Reynolds","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Isbel","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Szramka","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Wong","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Marabani","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mueed","family":"Mian","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Wood","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Shamdasani","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bird","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mansfield","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peta","family":"Pentony","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Nash","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Youssef","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Penglase","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvinka","family":"Jayalath","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Ciciriello","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Kempe","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed","family":"Fayez","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Oon","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreeya","family":"Patel","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunil","family":"Sharma","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chatfield","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Joshi","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Seah","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Truong","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suren","family":"Jayaweera","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talib","family":"Tahir","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Tsai","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Godfrey","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Racunica","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Chang","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen","family":"Loew","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Papandony","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Oh","sequence":"additional","affiliation":[{"name":"for the OPAL Rheumatology Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"issue":"6","key":"zoi230618r1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10093","key":"zoi230618r2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial.","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"zoi230618r3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"zoi230618r4","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.v71.11","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase iii, double-blind, randomized controlled trial.","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"zoi230618r5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"issue":"4","key":"zoi230618r6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40744-019-00177-4","article-title":"Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis.","volume":"6","author":"Reed","year":"2019","journal-title":"Rheumatol Ther"},{"issue":"10","key":"zoi230618r7","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration.","volume":"81","author":"Lauper","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"zoi230618r8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.v111.1","article-title":"Real-world evidence in EU medicines regulation: enabling use and establishing value.","volume":"111","author":"Arlett","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"zoi230618r9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2021-221307","article-title":"EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology.","volume":"81","author":"Courvoisier","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"zoi230618r10","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"5","key":"zoi230618r11","first-page":"874","article-title":"Using big data from real-world Australian rheumatology encounters to enhance clinical care and research.","volume":"38","author":"Littlejohn","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"16","key":"zoi230618r12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis.","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"issue":"9877","key":"zoi230618r13","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"zoi230618r15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review.","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"zoi230618r16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001113","article-title":"Risk of major adverse cardiovascular events among patients with rheumatoid arthritis after initial CT-based diagnosis and treatment.","volume":"6","author":"de Thurah","year":"2020","journal-title":"RMD Open"},{"key":"zoi230618r17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"mice: Multivariate imputation by chained equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"zoi230618r18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1080\/01621459.2015.1023805","article-title":"Stable weights that balance covariates for estimation with incomplete outcome data.","volume":"110","author":"Zubizarreta","year":"2015","journal-title":"J Am Stat Assoc"},{"issue":"12","key":"zoi230618r20","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1177\/0962280220932189","article-title":"Bootstrap inference for multiple imputation under uncongeniality and misspecification.","volume":"29","author":"Bartlett","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"6","key":"zoi230618r21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"zoi230618r22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi230618r23","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi230618r24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2020-217200","article-title":"Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework.","volume":"79","author":"Zhao","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"zoi230618r25","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2021-219951","article-title":"Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.","volume":"80","author":"Nabi","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"zoi230618r26","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2022-222439","article-title":"The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study.","volume":"81","author":"McDermott","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi230618r27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi230618r28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/annrheumdis-2013-203936","article-title":"The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.","volume":"74","author":"Harrold","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"zoi230618r29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry.","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"zoi230618r30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2020-217209","article-title":"Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.","volume":"80","author":"Pappas","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"zoi230618r31","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"zoi230618r32","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/annrheumdis-2015-207784","article-title":"Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.","volume":"75","author":"Kubo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"zoi230618r33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/art.v72.7","article-title":"Achievement of remission in two early rheumatoid arthritis cohorts implementing different treat-to-target strategies.","volume":"72","author":"Norvang","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"zoi230618r34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.","volume":"80","author":"Miyazaki","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"zoi230618r35","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/annrheumdis-2018-214544","article-title":"Time-dependent biases in observational studies of comparative effectiveness research in rheumatology: a methodological review.","volume":"78","author":"Iudici","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"zoi230618r36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1214\/17-AOAS1101","article-title":"Covariate balancing propensity score for a continuous treatment: application to the efficacy of political advertisements.","volume":"12","author":"Fong","year":"2018","journal-title":"Ann Appl Stat"},{"issue":"24","key":"zoi230618r37","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1002\/sim.v39.24","article-title":"Balancing vs modeling approaches to weighting in practice.","volume":"39","author":"Chattopadhyay","year":"2020","journal-title":"Stat Med"},{"key":"zoi230618r38","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"zoi230618r14","volume-title":"ICD-10: International Statistical Classification of Diseases and Related Health Problems","year":"2004"},{"key":"zoi230618r19","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"zoi230618r39","volume-title":"The Book of Why: The New Science of Cause and Effect","author":"Pearl","year":"2018"},{"key":"zoi230618r40","volume-title":"Causal Inference: What If","author":"Hern\u00e1n","year":"2020"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2806589\/deakin_2023_oi_230618_1686934990.90233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T11:33:06Z","timestamp":1688038386000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2806589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.20851","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}